
Feature|Videos|January 9, 2025
Capacity and Surge Response Leading Into a State of Readiness
Sustaining pandemic readiness requires investment in workforce, infrastructure, and scalable manufacturing practices.
Advertisement
Episodes in this series

Declining pandemic readiness is cause for concern; as such, the panelists highlight the importance of maintaining manufacturing capacity, a skilled workforce, and robust health infrastructure. Sustainable practices, including leveraging flu vaccine systems, are recommended for better future preparedness.
Advertisement
Related to this article

Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.

Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.

DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.

A second cereblon E3 ligase modulator from the Evotec and Bristol Myers Squibb degrader partnership is set to begin phase 1 testing in 2027.

Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.

mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.

Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.

Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.
Advertisement
Advertisement
Trending on BioPharm International
1
Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach
2
SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial
3
Visara Doses First Patient in Phase 2b Trial Pitting Bispecific VIS-101 Against Aflibercept in Wet AMD
4
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
5

